In a phase 1 trial mentioned earlier (NCT02541370), two of the nine patients (7 of PC, 2 of CRC) treated with CD133 CAR-T cells achieved an OR, two achieved a PR, and five were stable, all with grade 2–4 lymphopenia (CRS, Lee 2014 criteria; other adverse events, CTCAE v4.0) [245]. This evidence concerns the gene PROM1 and colorectal carcinoma.